✦ LIBER ✦

Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer

✍ Scribed by Young Joo Lee; Chang Geol Lee; Byoung Chul Cho; Gwi Eon Kim; Hye Jin Choi; Eun Chang Choi; Joo Hyuk Sohn; Joo-Hang Kim

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 160 KB
Volume: 32
Category: Article
ISSN: 1043-3074
DOI: 10.1002/hed.21177

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Background.

In locally advanced head and neck cancer, concurrent chemoradiotherapy (CRT) with combined 5‐fluorouracil (5‐FU) and cisplatin has increased acute toxicities as well as survival. Once‐weekly chemotherapeutic administration schedule may reduce severe toxicities. Thus, we investigated CRT using weekly administration of 5‐FU–cisplatin in locally advanced head and neck cancer.

Methods.

In a single‐arm, phase II study, CRT included radiation (70.0 Gy/35 fr) and weekly 5‐FU (750 mg/m^2^) and cisplatin (20 mg/m^2^).

Results.

Thirty‐two patients completed planned radiation. Thirteen (41%) achieved complete response, and 16 (50%) partial response. Twelve patients (38%) experienced acute grade 3 toxicities. Grade 3 mucositis, which was the most common toxicity, developed in 5 (16%) patients. The survival rates at 1 and 2 years were 81% and 76%, respectively. The progression‐free survival rates at 1 and 2 years were 69% and 66%, respectively.

Conclusions.

We demonstrated weekly 5‐FU‐cisplatin with conventional radiotherapy was efficacious and feasible with high compliance rate in locally advanced head and neck cancer. © 2009 Wiley Periodicals, Inc. Head Neck, 2010

📜 SIMILAR VOLUMES

Hyperfractionated accelerated radiothera

Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer

✍ Gabriele K. Beckmann; Florian Hoppe; Leo Pfreundner; Michael P. Flentje 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 267 KB 👁 2 views

## Background: The purpose of this study was to determine the feasibility and efficacy of hyperfractionated accelerated radiotherapy (hfrcb) combined with simultaneous chemotherapy with weekly cisplatin (cddp) in locally advanced inoperable head and neck cancer. ## Methods: From august 1999 to de

Weekly docetaxel, cisplatin, and 5-fluor

Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer

✍ Michael J. Overman; Syed M. Kazmi; Jagriti Jhamb; E Lin; James C. Yao; James L. 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 140 KB

Survival and toxicity differences betwee

Survival and toxicity differences between 5-day and weekly cisplatin in patients with locally advanced cervical cancer

✍ Mark H. Einstein; Akiva P. Novetsky; Madhur Garg; Susan M. Hailpern; Gloria S. H 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 144 KB

Phase 2 trial of concurrent 5-fluorourac

Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer

✍ Johnny Kao; Eric M. Genden; Vishal Gupta; Edelweiss L. Policarpio; Ryan J. Burri 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 362 KB

Randomized phase 2 study of concomitant

Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer

✍ Robert Haddad; Stephen Sonis; Marshall Posner; Lori Wirth; Rosemary Costello; Pa 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 272 KB 👁 1 views

## Abstract ## BACKGROUND: A randomized phase 2 study was performed to investigate the efficacy/toxicity of combining concomitant boost radiation and weekly carboplatin/paclitaxel with or without amifostine in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). ##

Paclitaxel, cisplatin, and 5-fluorouraci

Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck

✍ Maha Hussain; Shirish Gadgeel; Omer Kucuk; Wei Du; Walter Salwen; John Ensley 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 3 views

## BACKGROUND. The combination of cisplatin and 5-flurouracil (5-FU) is considered standard therapy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Paclitaxel has exhibited single-agent activity in patients with this disease. The authors conducted thi